The Efficacy of Metabolic Correction of Hyperhomocysteinemia in Hypertension
Homocysteine is considered as an independent ranked risk factor of cardiovascular complications. The objective of the study is to optimize therapy of hypertensive patients by additional oral administration of vitamin B complex and 1 mg of folic acid. Material and Methods. The study included 80 patients suffered from essential hypertension stage I–III, aged 58.29 ± 0.84 years. Patients were randomized to clinical groups. Patients of group A (n = 34) received treatment on the background of administration of angiotensin II receptor blocker and diuretic when necessary. Patients of group B
(n = 46) on the background of basic therapy were additionally administered homocysteine-lowering combination. Follow-up was three months. The control group consisted of 34 apparently healthy individuals. The level of total homocysteine was determined by immunoenzyme technique using Homocysteine EIA kit before and after treatment. Results. The level of homocysteine in group A did not change significantly (14.60 ± 1.09 mmol/l vs 13.60 ± 0.89 mmol/l; p > 0.05) and was higher than in the control group
(9.20 ± 0.56 mmol/l). In the group B it was observed homocysteine lowering by 22.7 % (p < 0.0001). Conclusions. In hypertensive patients we observed homocysteine elevation compared to apparently healthy individuals (p < 0.0001). Antihypertensive therapy does not affect the homocysteine concentration. Addition to antihypertensive therapy of vitamin complex and 1 mg of folic acid promotes significant reduction of homocysteine level in comparison with baseline (p < 0.0001).
Full Text:PDF (Українська)
Гомоцистеин — предиктор патологических изменений в организме человека / И.И. Мирошниченко, С.Н. Птицына, Н.Н. Кузнецова [и др.] // Русский медицинский журнал. — 2009. — Т. 17, № 4. — С. 224-228.
Adverse vascular effects of homocysteine are modulated by endothelium derived relaxing factors and relayed oxides of nitrogen / J. Stamler, J. Jsborne, O. Jaraki [et al.] // Journal of Clinical Investigation. — 1993. — Vol. 91, № 1. — P. 308-318.
A temporal association between folic acid fortification and an increase in colorectal cancer rates may be illuminating important biological principles: a hypothesis / J.B. Mason, A. Dickstein, P.F. Jacques [et al.] // Cancer Epidemiology, Biomarkers & Prevention Online. — 2007. — Vol. 16, № 7. — P. 1325-1329.
Bolander-Gouaille Ch. Homocysteine in the Development of Dementia — An Overview / Ch. Bolander-Gouaille // Bussines briefing: European pharmacotherapy. — 2005. — P. 1-8.
Changes in markers of cobalamin status after cessation of oral B-vitamin supplements in elderly people with mild cobalamin deficiency / S.J. Eussen, P.M. Ueland, G.J. Hiddink [et al.] // European Journal of Clinical Nutrition. — 2008. — Vol. 62, № 10. — P. 1248-1251.
Homocysteine is a risk factor for cerebral small vessel disease, acting via endothelial dysfunction / A. Hassan, B.J. Hunt, M. O’Sullivan [et al.] // Brain. — 2004. — Vol. 127, № 1. — P. 212-219.
Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis // JAMA. — 2002. — Vol. 288. — P. 2015-2022.
Jacobsen D.W. Homocysteine and vitamins in cardiovascular disease / D.W. Jacobsen // Clinical chemistry. — 1998. — № 44. — P. 1833-1843.
Lentz S.R. Homocysteine: Is it a clinically important cardiovascular risk factor? / S.R. Lentz, W.G. Haynes // Cleveland Clinic Journal of Medicine. — 2004. — Vol. 71. — P. 729-734.
Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task. Force document / G. Manciaa, S. Laurentb, E. Agabiti-Roseic [et al.] // Journal of Hypertension. — 2009. — Vol. 27. — 38 p.
Moat S.J. Plasma total homocysteine: instigator or indicator of cardiovascular disease? / S.J. Moat // Annals Clinical Biochemisry. — 2008. — Vol. 45, № 4. — P. 345-348.
Promotion of vascular smooth muscle growth by homocysteine: a link to atherosclerosis / J.C. Tsai, M.A. Perella, M. Yoshizumi [et al.] // Proceedings of the National Academy of Sciences of the United States of America (PNAS). — 1994. — Vol. 91, № 14. — P. 6369-6373.
Szegedi S.S., Castro C.C., Koutmos M., Garrow T.A. Betaine-homocysteine s-methyltransferase-2 is an s-methylmethionine–homocysteine methyltransferase / S.S. Szegedi, C.C. Castro, M. Koutmos [et al.] // The Journal of Biological Chemistry. — 2008. — Vol. 283, № 14. — P. 8939-8945.
Virtanen J.K. Homocysteine as a risk factor for CVD mortality in men with other CVD risk factors: the Kuopio Ischaemic Heart Disease Risk Factors (KIHD) Study / J.K. Virtanen, S. Voutilainen, G. Alfthan // Journal of Internal Medicine. — 2005. — Vol. 257, № 3. — P. 255-262.
Vollset S.E. Population determinants of Homocysteine / S.E. Vollset, H. Refsum, P.M. Ueland // American Journal of Clinical Nutrition. — 2001. — Vol. 73, № 3. — P. 499-500.
- There are currently no refbacks.
Copyright (c) 2016 HYPERTENSION
This work is licensed under a Creative Commons Attribution 4.0 International License.
© Publishing House Zaslavsky, 1997-2017